Receptors and targets in functional urology
Poster Session 15
-
Location:Room Berlin, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session The search for new pharmacological targets continues. Receptors and new mechanisms are being discussed in this session.
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Institutes: 1Kroto Research Institute, Dept. of Materials Science and Engineering, Sheffield, United Kingdom, 2Middle East Technical University (METU), Dept. of Biotechnology & BIOMATEN, METU Center of Excellence In Biomaterials and Tissue Engineering, Ankara, Turkey, 3METU, Dept. of of Biotechnology, Chemistry & BIOMATEN, METU Center of Excellence In Biomaterials and Tissue Engineering, Ankara, Turkey, 4Royal Hallamshire Hospital, Dept. of Urology, Sheffield, United Kingdom, 5METU, Dept. of of Biotechnology, Biological Sciences & BIOMATEN, METU Center of Excellence In Biomaterials and Tissue Engineering, Ankara, Turkey
Institutes: 1Tottori University Faculty of Medicine, Dept. of Urology, Yonago, Japan, 2University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America, 3Kochi Medical School, Dept. of Pharmacology, Nankoku, Japan, 4William Beaumont Hospital, Dept. of Urology, Royal Oak, United States of America
Institutes: 1The University of Tokyo Graduate School of Medicine, Dept. of Continence Medicine, Tokyo, Japan, 2Kissei Pharmaceutical Co., Ltd., Discovery Research R&D, Azumino, Japan, 3The University of Tokyo Graduate School of Medicine, Dept. of Urology, Tokyo, Japan
Institutes: 1University Hospital Bern, Dept. of Urology, Bern, Switzerland, 2Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland
Institutes: 1Faculty of Medicine of University of Porto, Dept. of Biomedical Science, Porto, Portugal, 2University of Porto, Dept. of Pharmacology & Therapeutics and MedInUP, Porto, Portugal, 3University of Southern California, Dept. of Urology and Obstetrics and Gynecology, Los Angeles, United States of America, 4University of Pittsburgh School of Medicine, Dept. of Medicine and Pharmacology-Chemical Biology, Pittsburgh, United States of America, 5University of Porto and CHSJ, Dept. of Biomedical Science and I3S-IBMC, Porto, Portugal, 6University of Porto, Dept. of Biomedical Science and I3S-IBMC, Porto, Portugal
Institutes: 1Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, 2University Hospital Bern, Dept. of Urology, Bern, Switzerland
Institutes: 1Renji Hospital, Dept. of Urology and Andrology, Shanghai, China, 2Shanghai 9th People’s Hospital, Dept. of Urology, Shanghai, China
Institutes: 1Urosphere, Dept of Pharmacology, Toulouse, France, 2Universidad Autónoma De Madrid, Dept. of Urology, Madrid, Spain, 3Palea Pharma & Biotech Consulting, , Toulouse, France
Institutes: 1UZ Leuven, Dept. of Urology, Leuven, Belgium, 2KU Leuven, Rega Institute For Medical Research, Leuven, Belgium, 3University of Antwerp, Dept. of Veterinary Sciences, Antwerp, Belgium, 4KU Leuven, Dept. of Pathology, Leuven, Belgium, 5University of Leipzig, Klinik Und Poliklinik Für Urologie, Leipzig, Germany